The ADVL0912 phase I/II study on 26 children receiving crizotinib for ALK-positive ALCL noted treatment-related grade ≥3 neutropenia (61.5%), lymphopenia, febrile neutropenia, myositis, and skin infection cases (3.8% each; no severe infection in the low-dose group) [144]. Here, ALK is linked to infection.